Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)

A. Grothey,M. Sugrue,E. Hedrick,D. M. Purdie,J. Yi,W. Dong,Mark Kozloff

Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)

2007

A. Grothey
M. Sugrue
E. Hedrick
D. M. Purdie
J. Yi
W. Dong
Mark Kozloff

4036 Background: While BV prolongs OS when used with standard 1st- or 2nd-line chemotherapy (CT) in mCRC, no data exist on the effects of BBP. A previous report from BRiTE showed favorable median O...

Keywords:

Bevacizumab
Colorectal cancer
Cancer research
Gynecology
Observational study
Medicine
Chemotherapy
overall survival
Internal medicine
Oncology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations